CAR-T Meeting 2022 | CARAMBA-1: a Phase I/IIa trial of autologous SLAMF7 CAR-Ts in multiple myeloma
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, outlines the rationale and preliminary results of CARAMBA-1, an ongoing Phase I/IIa clinical trial evaluating the feasibility, safety and anti-myeloma activity of autologous SLAMF7 chimeric antigen T-cells (CAR-T) in patients with multiple myeloma (NCT04499339). Recent pre-clinical studies have demonstrated that CAR-Ts targeting SLAMF7 have potent anti-myeloma efficacy. Early results from the dose-escalation part of the CARAMBA-1 study suggest that these CAR-Ts are safe and show indications of anti-tumor activity. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting in which was held virtually in 2022.
Transcript (edited for clarity)
CARAMBA is a project that is supported by the European Union in the Horizon2020 program. It’s a first-in-human Phase I-IIa clinical trial with a new CAR-T product to treat multiple myeloma. So new target antigen, SLAMF7, that we have characterized very well and demonstrated that CAR-Ts targeting this antigen confer very potent anti-myeloma efficacy in our pre-clinical models. And this is why we’ve brought this into this clinical trial...
CARAMBA is a project that is supported by the European Union in the Horizon2020 program. It’s a first-in-human Phase I-IIa clinical trial with a new CAR-T product to treat multiple myeloma. So new target antigen, SLAMF7, that we have characterized very well and demonstrated that CAR-Ts targeting this antigen confer very potent anti-myeloma efficacy in our pre-clinical models. And this is why we’ve brought this into this clinical trial. The clinical trial has approval in Germany, in Spain, and in Italy. We’re also awaiting the trial approval in France. We are demonstrating that innovations from an academic laboratory can be brought into a clinical trial. Also in several European countries, really catering to the European spirit.
In Phase I, we’re currently going through dose-escalation. We’ve treated the first patients and we’ve received a positive safety signal. We’re also seeing first indications of anti-myeloma efficacy. We can track the CAR-Ts in peripheral blood and therefore, are confident to go through the next dose levels. We’re now also entering dose levels where we’re anticipating to see more anti-myeloma efficacy. So the next few months will be very interesting, very exciting for this project. And I will share the latest update on this trial at the 4th European CAR-T meeting.
Read more...
